Maxigen Biotech Inc. (TPE:1783)

Taiwan · Delayed Price · Currency is TWD

40.90

+0.90 (2.25%)

Aug 19, 2026, 1:30 PM CST

-4.77% (1Y)

Market Cap	3.59B -6.8%
Revenue (ttm)	837.44M +9.4%
Net Income	291.20M +40.0%
EPS	3.22 +38.4%
Shares Out	89.68M
PE Ratio	12.43
Forward PE	n/a
Dividend	2.00 (4.97%)
Ex-Dividend Date	Sep 1, 2026

Volume	117,087
Open	40.05
Previous Close	40.00
Day's Range	40.05 - 41.00
52-Week Range	37.80 - 48.85
Beta	0.38
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2026

About Maxigen Biotech

Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone supplements; beauty and skincare products; and medical devices for ophthalmology, otolaryngology, dental, surgical, orthopedics, electronic instructions for use, and medical aesthetics, as well as engages in collagen purification activities. It also ... [Read more]

Industry Medical Instruments & Supplies

Sector Healthcare

Founded 1998

Country Taiwan

Stock Exchange Taiwan Stock Exchange

Ticker Symbol 1783

Full Company Profile

Financial Performance

In 2025, Maxigen Biotech's revenue was 811.56 million, an increase of 19.23% compared to the previous year's 680.65 million. Earnings were 265.31 million, an increase of 39.52%.

Financial Statements